glp-1/gip/glucagon receptor agonist Science Behind GLP 1 GIP and Glucagon Agonists for Obesity Research | News & Announcements GLP-1/GIP/Glucagon Triple Receptor Agonist -

Description

Very common (10% of patients) Nausea peaks during titration, typically subsides within 48 weeks at a stable dose Vomiting, diarrhoea, constipation Abdominal pain or discomfort Reduced appetite (this is the therapeutic effect, not an adverse effect) Less common but serious stop and see a doctor Severe, persistent abdominal pain radiating to the back possible pancreatitis Right upper abdomen pain, fever, yellowing possible gallstones / gallbladder disease Persistent neck lump, hoarseness, difficulty swallowing evaluate thyroid Rapid heartbeat, severe dehydration from vomiting Hypoglycaemia when semaglutide is combined with insulin or sulfonylureas What the Indian data shows: a 2025 study of Indian patients found GI side effects are the leading cause of discontinuation, peaking during dose escalation

Val(8)GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP/PS1 mice

What was once a relatively contained therapeutic class within endocrinology has expanded into a dual-purpose platform that operates across two distinct clinical domains